Literature DB >> 28810639

MicroRNA-200b inhibits pituitary tumor cell proliferation and invasion by targeting PKCα.

Yuanchuan Wang1, Xiaohong Yin1, Long Zhao1, Shun Li1, Jie Duan1, Renzhao Kuang1, Junwei Duan1.   

Abstract

The present study aimed to investigate the expression of miR-200b and protein kinase Cα (PKCα) in pituitary tumors and to determine whether miR-200b may inhibit proliferation and invasion of pituitary tumor cells. The regulation of PKCα expression was targeted in order to find novel targets for the treatment of pituitary tumors. In total, 53 pituitary tumor tissue samples were collected; these included 28 cases of invasive pituitary tumors and 25 cases of non-invasive tumors, in addition to 5 normal pituitaries. The expression level of miR-200b in the pituitary tumor tissue was detected by quantitative polymerase chain reaction (qPCR) and the expression of PKCα protein was detected by immunohistochemistry. A PKCα 3'untranslated region (UTR) luciferase vector was constructed and a dual luciferase reporter gene assay was employed in order to examine the effect of miR-200b on the PKCα 3'UTR luciferase activity. AtT-20 cells were transfected with miR-200b mimics, PKCα siRNA and miR-200b mimics + PKCα, and the changes in cellular proliferation, invasion and apoptosis were observed via MTT, Transwell assay and flow cytometric analysis. Furthermore, PKCα mRNA expression was determined by qPCR, and Western blotting was performed to detect the expression of PKCα protein. miR-200b revealed downregulation in invasive pituitary tumor tissue, and the expression level was significantly down-regulated compared with normal and non-invasive pituitary tumor tissue (P<0.01). In addition, the positive rate of PKCα protein expression in invasive pituitary tumor tissues was significantly higher than in normal and non-invasive tissues (P<0.01). PKCα protein levels are inversely correlated with miR-200b levels in invasive pituitary tumor tissues (r=-0.436, P=0.021). The dual luciferase reporter gene assay revealed that miR-200b could specifically bind to the 3'UTR of PKCα and significantly inhibit the luciferase activity by 39% (P<0.01). Upregulation of miR-200b or downregulation of PKCα could suppress cell proliferation and invasion, and increase apoptosis of AtT-20 cells. It was revealed that PKCα siRNA could suppress both proliferation and invasion of AtT-20 cells and partially simulate the function of miR-200b. Expression of PKCα mRNA and protein decreased significantly in AtT-20 cells overexpressing miR-200b. Additionally, miR-200b was significantly down-regulated in invasive pituitary tumor tissue and inversely correlated with PKCα protein levels. In conclusion, miR-200b inhibited proliferation and invasiveness and promoted the apoptosis of pituitary tumor cells by targeting PKCα. The observations of the present study indicate that miR-200b and PKCα may serve as promising therapeutic targets for invasive pituitary tumors.

Entities:  

Keywords:  AtT-20 cells; apoptosis; cell proliferation; invasion; invasive pituitary; miR-200b; pituitary tumor; protein kinase C-alpha

Year:  2017        PMID: 28810639      PMCID: PMC5526044          DOI: 10.3892/etm.2017.4681

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  45 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

3.  Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells.

Authors:  Wai Leong Tam; Haihui Lu; Joyce Buikhuisen; Boon Seng Soh; Elgene Lim; Ferenc Reinhardt; Zhenhua Jeremy Wu; Jordan A Krall; Brian Bierie; Wenjun Guo; Xi Chen; Xiaole Shirley Liu; Myles Brown; Bing Lim; Robert A Weinberg
Journal:  Cancer Cell       Date:  2013-09-09       Impact factor: 31.743

4.  Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas.

Authors:  Arianna Bottoni; Maria Chiara Zatelli; Manuela Ferracin; Federico Tagliati; Daniela Piccin; Cristina Vignali; George A Calin; Massimo Negrini; Carlo M Croce; Ettore C Degli Uberti
Journal:  J Cell Physiol       Date:  2007-02       Impact factor: 6.384

5.  The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.

Authors:  Susanna Leskelä; Luis J Leandro-García; Marta Mendiola; Jorge Barriuso; Lucía Inglada-Pérez; Iván Muñoz; Beatriz Martínez-Delgado; Andrés Redondo; Javier de Santiago; Mercedes Robledo; David Hardisson; Cristina Rodríguez-Antona
Journal:  Endocr Relat Cancer       Date:  2010-12-21       Impact factor: 5.678

6.  GH3B6 pituitary tumor cell proliferation is mediated by PKCalpha and PKCepsilon via ERK 1/2-dependent pathway.

Authors:  Juan Pablo Petiti; Silvina Gutiérrez; Ana Lucía De Paul; Verónica Andreoli; Claudia Mariela Palmeri; Liliana Del Valle Sosa; José Luis Bocco; Alicia Inés Torres
Journal:  Cell Physiol Biochem       Date:  2010-08-24

7.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

8.  TGF-β1 stimulates human Tenon's capsule fibroblast proliferation by miR-200b and its targeting of p27/kip1 and RND3.

Authors:  Jun Tong; Yuxuan Fu; Xinyu Xu; Shuxin Fan; Hong Sun; Ya Liang; Kai Xu; Zhilan Yuan; Yingbin Ge
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-28       Impact factor: 4.799

Review 9.  MicroRNAs in Human Pituitary Adenomas.

Authors:  Xu-Hui Li; Elaine Lu Wang; Hai-Meng Zhou; Katsuhiko Yoshimoto; Zhi Rong Qian
Journal:  Int J Endocrinol       Date:  2014-12-08       Impact factor: 3.257

10.  A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells.

Authors:  Ulrike Burk; Jörg Schubert; Ulrich Wellner; Otto Schmalhofer; Elizabeth Vincan; Simone Spaderna; Thomas Brabletz
Journal:  EMBO Rep       Date:  2008-05-16       Impact factor: 8.807

View more
  6 in total

Review 1.  Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.

Authors:  José Miguel Hinojosa-Amaya; César Ernesto Lam-Chung; Daniel Cuevas-Ramos
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-26       Impact factor: 5.555

2.  LncRNA XIST depletion prevents cancer progression in invasive pituitary neuroendocrine tumor by inhibiting bFGF via upregulation of microRNA-424-5p.

Authors:  Kai Zhou; Shaoshan Li; Guojia Du; Yandong Fan; Pengfei Wu; Hongjie Sun; Tingrong Zhang
Journal:  Onco Targets Ther       Date:  2019-09-02       Impact factor: 4.147

Review 3.  Recent advances in understanding corticotroph pituitary tumor initiation and progression.

Authors:  Ulrich Renner; Denis Ciato; Günter K Stalla
Journal:  F1000Res       Date:  2018-08-29

4.  Upregulation of miR-200b Inhibits Hepatocellular Carcinoma Cell Proliferation and Migration by Targeting HMGB3 Protein.

Authors:  Long-Kun Wang; Xi-Na Xie; Xu-Hong Song; Ting Su; Xiao-Lan Chang; Man Xu; Bin Liang; Dong-Yang Huang
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

Review 5.  MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary Adenomas.

Authors:  Ozal Beylerli; Narasimha M Beeraka; Ilgiz Gareev; Valentin Pavlov; Guang Yang; Yanchao Liang; Gjumrakch Aliev
Journal:  Int J Mol Sci       Date:  2020-10-02       Impact factor: 5.923

Review 6.  Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms.

Authors:  Vinaya Srirangam Nadhamuni; Márta Korbonits
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.